Table 4.
Competing risks regression analyses of all-cause mortality and allograft loss with natural log-transformed FGF23 (per 1 SD increase) and ascending tertiles of FGF23 as the primary exposure
| logFGF23 |
FGF23 Tertiles |
|||||
|---|---|---|---|---|---|---|
| Per 1 SD | P | 1 | 2 | 3 | Pa | |
| Outcome of all-cause mortality with allograft loss as competing risk | ||||||
| all patients, n = 984 | ||||||
| eGFR | 1.66 | <0.001 | Reference | 1.51 | 2.92 | <0.001 |
| 1.33, 2.07 | 0.78, 2.94 | 1.57, 5.45 | ||||
| eGFR, age, gender | 1.52 | <0.001 | Reference | 1.37 | 2.18 | 0.01 |
| 1.27, 1.84 | 0.71, 2.64 | 1.13, 3.99 | ||||
| restricted to patients with eGFR 30 to 90 ml/min per 1.73 m2, n = 765 | ||||||
| eGFR | 2.03 | <0.001 | Reference | 1.52 | 3.05 | 0.004 |
| 1.51, 2.73 | 0.68, 3.40 | 1.42, 6.57 | ||||
| eGFR, age, gender | 1.73 | <0.001 | Reference | 1.35 | 2.00 | 0.08 |
| 1.30, 2.29 | 0.61, 2.98 | 0.91, 4.41 | ||||
| Outcome of allograft loss with all-cause mortality as competing risk | ||||||
| all patients, n = 984 | ||||||
| eGFR | 1.37 | 0.007 | Reference | 1.40 | 2.75 | <0.001 |
| 1.09, 1.71 | 0.64, 3.09 | 1.40, 5.38 | ||||
| eGFR, age, gender | 1.32 | 0.002 | Reference | 1.41 | 2.97 | <0.001 |
| 1.11, 1.57 | 0.64, 3.11 | 1.50, 5.88 | ||||
| restricted to patients with eGFR 30 to 90 ml/min per 1.73 m2, n = 765 | ||||||
| eGFR | 1.38 | 0.06 | Reference | 1.56 | 2.48 | 0.01 |
| 0.98, 1.93 | 0.69, 3.53 | 1.19, 5.18 | ||||
| eGFR, age, gender | 1.30 | 0.04 | Reference | 1.59 | 2.69 | 0.007 |
| 1.01, 1.68 | 0.70, 3.60 | 1.28, 5.67 | ||||
aP for linear trend.